PC-002 International Multicenter Phase II Clinical Trial in Beijing Cancer Hospital Launches Patient Recruitment

Recently, Cothera Bioscience, the parent company of Percans Oncology, has made new progress in the Phase II clinical trial of MYC gene inhibitor PC-002 in China. Beijing Cancer Hospital is conducting a multicenter, open-label, exploratory dose-ranging phase II study of Sepantronium Bromide in patients with relapsed/refractory c-Myc rearranged high-grade B-cell lymphoma (HGBCL) (clinical trial approval number: 2022LP00392). The study has been approved by the Ethics Committee of Beijing Cancer Hospital. The clinical trial is open to public for patient recruitment. All patients with relapsed/refractory c-Myc rearranged HGBCL who meet the requirements after screening will have the opportunity to participate in the study.

This multi-center clinical trial will be conducted at medical centers in Beijing, Shanghai, Guangzhou, Tianjin, Wuhan and Zhengzhou.

PC-002, the core product of Cothera Bioscience, is a first-in-class small molecule drug targeting MYC-mutated tumors. With a unique mechanism of action (MOA), PC-002 selectively induces MYC protein degradation and cell apoptosis in MYC-dependent tumors. With more than 50% of human cancers showing increased expression, MYC is regarded as one of the most important yet “undruggable” cancer targets. Via its unique mechanism, PC-002 selectively kills tumor cells with MYC mutation and may potentially target multiple indications in cancers.

About the company

Cothera Bioscience was formed by the founding core members of CrownBio, a well-known Contract Research Organization specializing in oncology, to develop innovative, targeted cancer therapies.

Cothera Bioscience has developed a series of new product pipelines for cancer in the areas of synthetic lethality and immunotherapy, and has filed a number of international and domestic patents for its R&D results.

Source